52nd week of 2012 patent applcation highlights part 41 |
Patent application number | Title | Published |
20120328617 | METHOD FOR INHIBITING ANGIOGENESIS - The present invention relates to a method for inhibiting angiogenesis using a peroxiredoxin II (Prx II) inhibitor, and a method for preparing angiogenesis-inhibiting medicines using Prx II inhibitor. According to the present invention, the inhibitor of Prx II gene expression or Prx II protein activity increases oxidative inactivation of VEGF receptor tyrosine kinase (RTK) to reduce VEGF signaling, thereby screening a novel angiogenesis inhibitor. Therefore, the method of the present invention can be used for the prevention or treatment of various diseases, ailments, and conditions related to angiogenesis. | 2012-12-27 |
20120328618 | DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY - The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose.In some embodiments, a third dose of said antibody is administered for a third period of time. This dosage regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The present invention also relates to the use of a CD19×CD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method of the present invention. A pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods/dosage regimen of the present invention is disclosed as well. | 2012-12-27 |
20120328619 | Trispecific Therapeutics Against Acute Myeloid Leukaemia - The present invention relates to a molecule having binding specificities for (a) CD123; (b) CD16 and (c) CD33. The present invention further relates to the molecule of the invention, wherein the molecule comprises a first immunoglobulin domain comprising a V | 2012-12-27 |
20120328620 | EPIDERMALGROWTH FACTOR RECEPTOR MUTATIONS - Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3′-kinase (“PI3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant PI3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described. | 2012-12-27 |
20120328621 | IMMUNOGENS, COMPOSITONS AND USES THEREOF, METHOD FOR PREPARING SAME - The invention relates to fusion proteins comprising an amino acid sequence of a fragment H corresponding to a fragment of a calcium binding protein excreted-secreted by adult worms of | 2012-12-27 |
20120328622 | NOVEL COMPOUNDS - The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 2012-12-27 |
20120328623 | ANTI-erbB3 ANTIBODY - The present invention relates to an antibody or an antibody fragment thereof which recognizes an extracellular domain of erbB3 and inhibit EGF-like ligand-dependent phosphorylation of erbB3, a DNA encoding the antibody or the antibody fragment thereof, a method of producing the antibody or the antibody fragment thereof, a therapeutic drug including the antibody or the antibody fragment thereof, and therapeutic application using the antibody or the antibody fragment thereof. | 2012-12-27 |
20120328624 | ANTI-DLL3 ANTIBODY - It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention. | 2012-12-27 |
20120328625 | TARGETED BINDING AGENTS DIRECTED TO SONIC HEDGEHOG HOMOLOG AND USES THEREOF - The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics. | 2012-12-27 |
20120328626 | METHOD FOR INCREASING N-GLYCOSYLATION SITE OCCUPANCY ON THERAPEUTIC GLYCOPROTEINS PRODUCED IN PICHIA PASTORIS - Described is a method for increasing the N-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the N-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex, for example, the | 2012-12-27 |
20120328627 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF - The present invention relates to a compound represented by formula (I): | 2012-12-27 |
20120328628 | ANTIBODIES TO CONFORMATIONALLY TRAPPED PROTEINS - The present invention provides methods for generating antibodies to specific conformations of proteins. The conformation specific antibodies of the invention can be put to a variety of uses including diagnosis and treatment of diseases and for screening for compounds that induce conformational changes in proteins upon binding. | 2012-12-27 |
20120328629 | Therapeutic Applications Targeting SARM1 - The present disclosure provides methods for reducing axonal and/or synaptic degradation in neurons by modulating sterile α/Armadillo/Toll-Interleukin receptor homology domain protein (SARM) activity and/or expression. | 2012-12-27 |
20120328630 | METHODS FOR TREATING AND/OR LIMITING DEVELOPMENT OF DIABETES - The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes. | 2012-12-27 |
20120328631 | EP1 INHIBITION - Provided herein are methods of accelerating bone fracture healing in a subject. Also provided herein are methods of treating or preventing osteoporosis in a subject. Further provided are methods of screening for an agent that accelerates bone fracture healing or treats or prevents osteoporosis. | 2012-12-27 |
20120328632 | INHIBITION OF LEUKOCYTE ADHESION - This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34. | 2012-12-27 |
20120328633 | T CELL ACTIVATION INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND SCREENING METHOD FOR T CELL ACTIVATION INHIBITING SUBSTANCE - Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM. | 2012-12-27 |
20120328634 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate. | 2012-12-27 |
20120328635 | CHAPERONIN 10 VARIANTS - The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs). | 2012-12-27 |
20120328636 | KDR PEPTIDES AND VACCINES COMPRISING THE SAME - The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines. | 2012-12-27 |
20120328637 | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF THE INTERLEUKIN-35 RECEPTOR COMPLEX - The receptor for Interleukin 35 (IL-35) is provided. The Interleukin 35 Receptor (IL-35R) comprises a heterodimeric complex of the Interluekin12Rβ2 receptor and the gp130 receptor. Various compositions comprising the IL-35R complex, along with polynucleotides encoding the same and kits and methods for the detection of the same the same are provided. Methods of modulating the activity of IL-35R or modulating effector T cell functions are also provided. Such methods employ various IL-35R antagonists and agonists that modulate the activity of the IL-35R complex and, in some embodiments, modulate effector T cell function. Further provided are methods for screening for IL-35R binding agents and for IL-35R modulating agents. Various methods of treatment are further provided. | 2012-12-27 |
20120328638 | MYBL2 PEPTIDES AND VACCINES CONTAINING THE SAME - Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the MYBL2 gene that bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility, more particularly peptides having the amino acid sequence of SEQ ID NO: 5 and fragments thereof, are provided. The present invention further extends to peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, provided they retain cytotoxic T cell inducibility. Also provided as nucleic acids encoding any of the aforementioned peptides, antigen-presenting cells and isolated CTLs that target such peptides, and pharmaceutical agents and compositions including any of the aforementioned peptides, nucleic acids, and APCs as active ingredients. The components of the present invention have particular utility in connection with the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a postoperative recurrence thereof. | 2012-12-27 |
20120328639 | IMMUNOGENIC LHRH COMPOSITIONS AND METHODS RELATING THERETO - The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics or the treatment of disorders of the reproductive organs. | 2012-12-27 |
20120328640 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER - The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3α/CCL20 or β-defensin mDF2β. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer. | 2012-12-27 |
20120328641 | CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS - Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed. | 2012-12-27 |
20120328642 | BOTULINUM NEUROTOXIN ANTIGENIC COMPOSITIONS AND METHODS - Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided. | 2012-12-27 |
20120328643 | OUTER MEMBRANE VESICLE (OMV) VACCINE COMPRISING N. MENINGITIDIS SEROGROUP B OUTER MEMBRANE PROTEINS - A composition comprising (a) | 2012-12-27 |
20120328644 | Low Antigen-dose Immunization for Maximizing T-helper Cell 1 (Th1) Immunity Against a Pathogen - Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and methods is substantially lower than dosages conventionally used in the field. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response. | 2012-12-27 |
20120328645 | Malaria Vaccines - Transcript profiles for irradiated and non-irradiated | 2012-12-27 |
20120328646 | Globo H and Related Anti-Cancer Vaccines with Novel Glycolipid Adjuvants - An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker. | 2012-12-27 |
20120328647 | FORMULATIONS COMPRISING EXTRACTS FROM PRIMITIVE PLANT SPECIES (Mosses, Ferns and Lichens) TO TREAT AND PREVENT CANCERS - Disclosed are extracts prepared from primitive plants and fungi that have anti-cancer properties. The extracts are prepared by pulverizing the biological matter in a diluent. The extract can be administered to an individual or animal to kill cancer cells, prevent growth of cancer cells and treat cancer. The extracts may be used in combination with other therapeutic protocols. | 2012-12-27 |
20120328648 | Method For Growing Fibroblasts - A method for reducing the occurrence of wrinkles in skin caused by aging by promoting the growth of fibroblasts, which have a declined cellular proliferative potential due to aging or adverse affects from ultraviolet light or active oxygen. The method includes the steps of providing an agent that contains a yeast extract and a safflower extract as effective constituents, and applying the agent to skin to promote the growth of fibroblasts. | 2012-12-27 |
20120328649 | Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus - The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to yellow fever virus. The invention provides recombinant viral vectors based on the non-replicating modified vaccinia virus Ankara or based on a D4R-defective vaccinia virus. When administered according to methods of the invention, the recombinant viral vectors induce a broad immune response to yellow fever virus and demonstrate an excellent safety profile. | 2012-12-27 |
20120328650 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 2012-12-27 |
20120328651 | CHIMPANZEE ADENOVIRUS VACCINE CARRIERS - The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer. | 2012-12-27 |
20120328652 | RECOMBINANT ATTENUATED PARVOVIRUS - The invention is in the field of virus vaccines for protecting animals against infection by | 2012-12-27 |
20120328653 | MODIFIED IMMUNIZATION VECTORS - The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic. | 2012-12-27 |
20120328654 | MULTI-PHASE EMULSIONS BASED ON AMPHIPHILIC BLOCK COPOLYMERS - A method for enhancing a body's response to an immunogen is disclosed. The method comprises immunizing a subject in need thereof a vaccine composition in a water-in-oil (W/O/W) emulsion that comprises (a) an antigen; and (b) an adjuvant composition in a W/O/W emulsion. The adjuvant composition comprises: (i) a continuous aqueous phase comprising H | 2012-12-27 |
20120328655 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR INDUCING HUMORAL AND CELLULAR IMMUNE RESPONSES - Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial. | 2012-12-27 |
20120328656 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 2012-12-27 |
20120328657 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 2012-12-27 |
20120328658 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 2012-12-27 |
20120328659 | TREATMENT OF STREPTOCOCCAL INFECTIONS - Immunogenic compositions and methods of treating a | 2012-12-27 |
20120328660 | IMMUNOGENIC COMPOSITIONS USEFUL IN PROVOKING AN INTEGRATED RESPONSE TO TUMOR ANTIGENS - The invention relates to an immunogenic composition and its use. It comprises “OLPs,” or overlapping peptides, derived from a longer, tumor antigen, in combination with polyICLC, and Montanide. | 2012-12-27 |
20120328661 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2012-12-27 |
20120328662 | COMPOSITION FOR INHIBITING TUMOR CELL PROLIFERATION - This invention pertains to cancer immunotherapy, by providing a proinflammatory dendritic cell (DC), which has been stimulated to maturation ex vivo by specific treatment, a method for such treatment and a composition comprising the proinflammatory DC. The DC may be used as a cell based immunotherapy for inhibiting tumor cell proliferation. | 2012-12-27 |
20120328663 | Composition of Beta-Glucan and Ashwagandha - Compositions including combinations of β-glucan and | 2012-12-27 |
20120328664 | LIQUID FORMULATIONS - Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow. | 2012-12-27 |
20120328665 | COMPOSITE NANOPARTICLE, AND PREPARATION PROCESS AND USE THEREOF - Disclosed herein are a composite nanoparticle and a process for preparing the same. The composite nanoparticle includes Rev peptides chemically bonded to gold. Also disclosed herein are a pharmaceutical composition including a plurality of the aforesaid composite nanoparticles, and a method of inhibiting tumor/cancer cells by virtue of the aforesaid composite nanoparticle. | 2012-12-27 |
20120328666 | ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide. | 2012-12-27 |
20120328667 | IN SITU CONSTITUTING A VACCINE FOR ADMINISTRATION TO A PREDETERMINED HERD OF ANIMALS - The present invention pertains to a method for constituting a vaccine for administration to a predetermined herd of animals, comprising providing a set of multiple distinct non-live antigens, each non-live antigen being present in a lyophilised form and packed in a container, providing a liquid carrier which is pharmaceutically acceptable for the animals, determining health risks in connection with microbial infection for this herd, establishing which one or more non-live antigens in the said set correspond to these health risks, taking one or more of the containers corresponding to the one or more non-live antigens and mixing the lyophilised contents of the said one or more containers with the carrier to constitute the vaccine. The invention also pertains to a method to produce multiple distinct non-live antigens suitable for constituting the vaccine, a kit of parts and a method enabling in situ constitution of the vaccine. | 2012-12-27 |
20120328668 | MODIFIED SIRNA MOLECULES AND USES THEREOF - The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided. | 2012-12-27 |
20120328669 | High density fibrous polymers suitable for implant - This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers. | 2012-12-27 |
20120328670 | Targeted Delivery of Retinoid Compounds to the Sebaceous Glands - Disclosed herein are topical dermal compositions comprising particles, wherein the particles comprise | 2012-12-27 |
20120328671 | COMPOSITION - The invention relates to products comprising an antibiotic agent and a second agent being a dispersant or an anti-adhesive agent, in particular a mucolytic dispersant or a mucolytic anti-adhesive agent, which are useful in relation to the prevention and treatment of bacterial infections. | 2012-12-27 |
20120328672 | COMPOSITION AND METHOD OF SEPARATING BENTONITE INTO PARTICLES HAVING DISCRETE SIZE AND DENSITY RANGES CAPABLE OF BINDING BIOLOGICAL TOXINS AND CHEMOTHERAPEUTIC AGENTS. - A low heavy metal (i.e. cadmium, mercury) containing calcium aluminum silicate product produced by the method of Air Classification. The method comprises using an air classification system for separating a cadmium containing calcium aluminum silicate feed stock into at least a first fraction and a second fraction. The first separation fraction contains material having an average particle size over 100 um, and the second fraction contains material having an average particle size under 100 um. | 2012-12-27 |
20120328673 | DENDRITIC AND HYPERBRANCHED POLYMERS FOR CELLULAR ENCAPSULATION AND FUNCTIONALIZATION - A protective coating for covering a biological material, the protective coating having a plurality of interconnected layers covalently bonded to each other. The plurality of interconnected layers can include at least one hyperbranched polymeric material, and at least one dendrimer. A method of forming a protective coating for covering a biological material, the method can include depositing a plurality of interconnected layers, which are covalently bonded to each other. The plurality of interconnected layers can include at least one hyperbranched polymeric material, and at least one dendrimer. | 2012-12-27 |
20120328674 | NON-TOXIC AND ENVIRONMENTALLY COMPATIBLE PHOTO-PROTECTIVE PREPARATIONS - The present invention relates generally to methods and compositions for prophylaxis and treatment of skin conditions. Topical compositions which protect the skin from UV radiation damage and treat UV radiation damage done to the skin are provided according to embodiments of the present invention which include at least one cyanin derived from a plant and at least one additional agent selected from the group consisting of: a UV radiation reflector, a UV screening agent, niacinamide, and a combination of two or more thereof. | 2012-12-27 |
20120328675 | FILM PREPARATION CONTAINING MEDICAMENT WITH UNPLEASANT TASTE - Provided is a film preparation in which an unpleasant taste derived from a medicament is masked. The film preparation includes coating layers containing no terpene formed on both sides of a medicament-containing layer containing a medicament having an unpleasant taste and a terpene. | 2012-12-27 |
20120328676 | DIKETOPIPERAZINE SALTS FOR DRUG DELIVERY AND RELATED METHODS - Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization. | 2012-12-27 |
20120328677 | Active Agent Formulations, Methods of Making, and Methods of Use - An active agent composition includes particles containing a water-insoluble active agent or an active agent with a significant food effect; and a ternary amine polymer having both hydrophobic (meth)acrylate units and acid-soluble (meth)acrylate units, and an acidifying agent; wherein upon ingestion by a human subject, the acidifying agent facilitates the dissolution of the ternary amine polymer in the gastrointestinal tract. | 2012-12-27 |
20120328678 | Hydrogel Networks Having Living Cells Encapsulated Therein - The present invention is directed to a hydrogel network comprised of a physically cross-linked polymer and a chemically cross-linked polymer or physically entangled copolymer containing living cells, such as chondrocytes, encapsulated therein. In a preferred aspect, the physically cross-linked polymer is selected from the group consisting of thermally gelling polysaccharides and proteins, such as agarose or gelatin, and the chemically cross-linked or physically entangled polymer is synthesized from a water-soluble vinyl monomer, either as a homopolymer or copolymer, such as polyethylene glycol diacrylate (“PEG-DA”) and 2-hydroxyethyl methacrylate (“HEMA”). | 2012-12-27 |
20120328679 | SOLID PHARMACEUTICAL DISPERSIONS WITH ENHANCED BIOAVAILABILITY - Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment. | 2012-12-27 |
20120328680 | Wound Treatment Therapy - The wound treatment therapy deactivates pathogenic microorganisms within the wound environment without disrupting the cell walls. The wound treatment therapy of this invention combines the application of stabilized hypochlorous acid compound with the application of a hydrophobic wound dressing. The application of hypochlorous acid provides the initial anti-microbial agent, which disrupts and eradicates biofilm, as well as, deactivates the harmful pathogenic organisms within the wound environment. The application of the hydrophobic wound dressing, which is designed to bind harmful hydrophobic microorganisms and toxins, provides a mechanical vehicle for physically removing deactivated hydrophobic microorganisms form the wound environment with each dressing change. | 2012-12-27 |
20120328681 | CERIA FOR USE AS AN ANTIMICROBIAL BARRIER AND DISINFECTANT IN A WOUND DRESSING - The present invention relates to protecting a human from an infection using a disinfecting agent as described herein and a method for use thereof, more particularly to a rare earth-containing device for protecting a wound and a method for use thereof. | 2012-12-27 |
20120328682 | PARTICLES INCORPORATING ANTIMICROBIAL AGENTS - The present invention relates generally to particles that include one or more antimicrobial agents therein and/or thereon. The particles may be provided with one or more coatings that contain one or more antimicrobial agents, or the one or more antimicrobial agents may be embedded in the particles. The present invention also relates to goods such as medical devices, personal care products, and household devices that incorporate one or more antimicrobial particles. The goods may be provided with one or more coatings that contain the antimicrobial particles, or the antimicrobial particles may be physically embedded in the medical devices. The present invention is further directed towards methods of making such medical devices. The goods incorporating the antimicrobial particles may be used in accordance with methods of killing microorganisms and preventing infections. | 2012-12-27 |
20120328683 | Alkylaminoalkyl oligomers as broad-spectrum antimicrobial agent - The present application relates to oligomeric antimicrobial compounds and compositions comprising the same. The oligomers are formed by polymerizing aminoalkyl (meth)acrylate or aminoalkyl (meth)acrylamide monomer(s). In addition to imparting materials with broad spectrum antimicrobial activity, the oligomers can impart antimicrobial activity to substrates such as hair and skin. | 2012-12-27 |
20120328684 | CITROBACTER FREUNDII ANTIBACTERIAL AGENTS AND THEIR USE - Provided herein are methods for treating planktonic bacteria or a biofilm. The methods include contacting the planktonic bacteria or biofilm with an effective amount of an isolated | 2012-12-27 |
20120328685 | SYSTEM FOR PROTECTING GOODS DURING TRANSPORT - A system for protecting stored goods in a container ( | 2012-12-27 |
20120328686 | Pharmaceutical Composition Comprising miRNA-100 And Its Use in the Modulation Of Blood Vessel Growth and Endothelial Inflammation - Disclosed is a pharmaceutical composition comprising a miRNA-100 molecule or an antagomir thereof or a variant thereof for use as a medicament for the positive or negative modulation of blood vessel growth and vascular inflammation wherein the miRNA-100 or the miRNA antagomir has a homology of at least 85% to any of SEQ ID NO:1, 2, 3 and/or 9. | 2012-12-27 |
20120328687 | FORMULATIONS OF SELECTIVE ALPHA-2 AGONISTS AND METHODS OF USE THEREOF - The invention provides compositions and methods utilizing low concentrations of selective α-2 adrenergic receptor agonists, preferably, brimonidine. The invention provides contact lens solutions and methods of using these solutions for pre-soaking contact lenses to achieve reduction of redness and/or increase in whitening of eyes. The invention also provides compositions including a selective α-2 adrenergic receptor agonist in a combination with an ocular medical device, including but not limited to a bandage lens. The invention also provides combination compositions including a selective α-2 adrenergic receptor agonist and another active agent for the treatment of an ocular condition, including but not limited to glaucoma and/or a condition associated with eye redness. | 2012-12-27 |
20120328688 | BIOCOMPATIBLE FILM WITH VARIABLE CROSS-SECTIONAL PROPERTIES - A biocompatible film includes a single layer having a plurality of components, at least one of the plurality of components having a predetermined non-uniform distribution in the thickness direction of the single layer. The at least one of the plurality of components that has a non-uniform distribution in the thickness direction of the single layer may have a substantially uniform distribution in the longitudinal and lateral directions of the single layer. The biocompatible film can be made by depositing a fluid composition including a film forming material and at least one other component immiscible with the film forming material and having a density different than the film forming material into a single layer, and drying the single layer such that the at least one other component has a predetermined non-uniform distribution in the thickness direction of the single layer after drying. | 2012-12-27 |
20120328689 | DEODORIZING PAPER AND METHOD - A deodorizing paper substrate is provided that has a base sheet that incorporates between 3%-15% of sodium bicarbonate. The deodorizing particles remove malodors from any environment. An associated method of manufacture is also provided. | 2012-12-27 |
20120328690 | Amniotic Membrane Preparations and Purified Compositions and Anti-Inflammation Methods - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 2012-12-27 |
20120328691 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. | 2012-12-27 |
20120328692 | POTENT D-PEPTIDE ANTAGONISTS OF MDM2 AND MDMX FOR ANTICANCER THERAPY - The present invention relates to a group of MDM2 and MDMX antagonists, namely, D-peptides, variants thereof, and stapled D-peptides, along with pharmaceutical compositions comprising the antagonists, and methods of treating conditions such as cancer using the antagonists. | 2012-12-27 |
20120328693 | METHOD FOR ENHANCING IMMUNE RESPONSE IN THE TREATMENT OF INFECTIOUS AND MALIGNANT DISEASES - The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response. | 2012-12-27 |
20120328694 | THERAPEUTIC AGENT FOR FIBROID LUNG - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent. | 2012-12-27 |
20120328695 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC FATIGUE - Pharmaceutical compositions and methods for the treatment of chronic fatigue in human patients comprising a central nervous system (CNS) stimulant in a daily low-dosage amount in combination with therapeutically effective daily amounts of micronutrients, comprising acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS and micronutrient components may be in an oral dosage composition containing a low dosage amount of CNS stimulant such as about 2.5 mg methylphenidate HCl together with about 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cysteine, and 25-100 mg alpha-lipoic acid. | 2012-12-27 |
20120328696 | ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER - The present application describes a composition comprising a neuroprotective effective amount of an antioxidant acetylsalicylic acid maltol ester (AME). | 2012-12-27 |
20120328697 | Controlled Release Solid Dose Forms - The present invention is directed to a solid dose form comprising a film coating composition encapsulating a core, wherein: (i) the core comprises an active ingredient comprising at least one of a pharmaceutical, veterinary, or nutraceutical active ingredient; (ii) the film coating composition comprises ethylcellulose and guar gum, wherein the guar gum has an apparent viscosity ≧151.0 cps at a shear rate of 50 s | 2012-12-27 |
20120328698 | COATING METHOD - The present invention concerns a method for coating granules comprising mesalazine, with a coating mixture comprising two polymers, polymer I and polymer II; said polymer I being selected to allow formation of a closing membrane around said granules in the absence of said polymer II, and said polymer II being selected to act as a water-soluble pore former in said coating mixture; wherein a) the amount of polymer I is adjusted to provide a closing membrane in the absence of polymer II, and b) the amount of polymer II in said coating mixture is adjusted to obtain coated granules which exhibit controlled release of mesalazine. The invention further concerns a product obtainable by the coating method. | 2012-12-27 |
20120328699 | METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS - The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP). | 2012-12-27 |
20120328700 | METHODS AND COMPOSITIONS FOR REGENERATING CONNECTIVE TISSUE - Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament. | 2012-12-27 |
20120328701 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR - The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof. | 2012-12-27 |
20120328702 | NANOPARTICLE COMPOSITIONS - The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions associated with the epidermal and/or dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, actinic keratosis, facial wrinkles, muscle contracture, and headache. Methods generally involve administering nanoparticle compositions to the skin. | 2012-12-27 |
20120328703 | SWELLABLE PARTICLES FOR DRUG DELIVERY - Swellable particles for delivery of a drug or other working agent to the pulmonary system are provided. The swellable particles include a dehydrated (dry) aerodynamic particle diameter of 5 μm or less to enable delivery to the respiratory tract, such as for example to the tracheo-bronchial airways of the upper respiratory tract and/or to the alveolic regions of the deep lung, and a hydrated particle diameter that is greater than 6 μm volume mean diameter to retard or prevent their phagocytosis by the macrophages present in airways of the respiratory tract. | 2012-12-27 |
20120328704 | POWDER COMPOSITIONS FOR INHALATION - The present invention relates to newly identified genes that encode proteins that are involved in the synthesis of L-ascorbic acid (hereinafter also referred to as Vitamin C). The invention also features polynucleotides comprising the full-length polynucleotide sequences of the novel genes and fragments thereof, the novel polypeptides encoded by the polynucleotides and fragments thereof, as well as their functional equivalents. The present invention also relates to the use of said polynucleotides and polypeptides as biotechnological tools in the production of Vitamin C from microorganisms, whereby a modification of said polynucleotides and/or encoded polypeptides has a direct or indirect impact on yield, production, and/or efficiency of production of the fermentation product in said microorganism. Also included are methods/processes of using the polynucleotides and modified polynucleotide sequences to transform host microorganisms. The invention also relates to genetically engineered microorganisms and their use for the direct production of Vitamin C. | 2012-12-27 |
20120328705 | MAGNETIC NANOMEDICINE FOR TUMOR SUPPRESSION AND THERAPY - A magnetic nanomedicine for tumor suppression and therapy, comprising: a core, made of magnetic nanoparticles; a shell, encapsulating said core and is made of carboxylated polyaniline (SPAnH); and a tumor suppression medicine Epirubicin (EPI) or Doxorubicin (DOX) covalently bonded onto said shell. Said magnetic nanomedicine is capable of improving its thermal stability, and it can be dissolved uniformly in water, plus its superparamagnetic property, thus it can be guided by an outside magnetic field to concentrate to the site of tumor distribution to increase the local medicine concentration and enhance therapy effect. | 2012-12-27 |
20120328706 | POLYMER PARTICLE DELIVERY COMPOSITIONS AND METHODS OF USE - The present invention provides biodegradable polymer particle delivery compositions based on polymers, such as polyester amide (PEA) and polyester urethane (PEUR) polymers, that contain amino acids in the polymer. The polymer particle delivery compositions can be formulated as a liquid dispersion of polymer particles with the bioactive agents dispersed in the particle or conjugated attached to polymer molecules or particle surfaces. The bioactive agents can include drugs, polypeptides, DNA and cells for cell-based therapies using particles sized for local, mucosal or circulatory delivery. Methods of treating a disease by administering to a subject the polymer particle delivery composition, which incorporates a bioactive agent suitable for treatment of the disease, or its symptoms, are also included. | 2012-12-27 |
20120328707 | MULTI-PARTICULATE PHARMACEUTICAL FORMULATION FOR COLON ABSORPTION - Multi-particulate pharmaceutical composition, the particles having a particle size of between 2.2 and 4 mm, preferably 2.5 to 3.1 mm and most preferably about 2.8 mm, each particle comprising: (a) a core containing or carrying at least one pharmaceutically active agent; and (b) at least one layer showing adhesion and/or being crushable in the colon comprising (i) one or more poly(meth)acrylates, and (ii) non-porous inert lubricant, selected from the group consisting of stearates, kaolin, pharmaglass, talcum and mixtures thereof. | 2012-12-27 |
20120328708 | DISINFECTANT COMPOSITION AND ITS USE IN DENTAL TREATMENT - The present invention concerns a disinfectant or antimicrobial composition for use in dental treatment, such as treatment and/or prevention of periodontitis, gingivitis or other forms of oral infection. The present Inventor found that microorganisms that infect the dental tissues and cause inflammation thereof, are susceptible to osmotic stress, to such extent that the application of a hypertonic composition is effective in curing or preventing infection and/or inflammations. It was furthermore found that these microorganisms are also susceptible to acidic stress. The present invention therefore provides compositions that induce osmotic stress in microorganisms causing infection of dental tissue when topically applied thereto, preferably osmotic as well as acidic stress. The present invention also concerns the methods and uses involving the compositions of the invention. | 2012-12-27 |
20120328709 | METHODS OF DISSOLVING BLOOD CLOTS AND THE LIKE - The present invention provides an aqueous composition and its use for dissolving blood clots in vivo or in clinical or research samples in vitro, said composition comprising at least one chaotropic agent, at least one chelating agent that complexes iron if the chaotropic agent does not complex iron and at least one surface-active emulsifier, the composition being buffered near pH 7.4. The process of dissolving the clot with the aqueous composition is advantageous because it is simple, inexpensive, rapid and can be applied in a variety of contexts, including basic research and clinical situations. | 2012-12-27 |
20120328710 | Selective, site-activated binding of toxins at target sites - The teachings provided herein generally relate to site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites. More particularly, the systems taught here include a phenolic compound bound to a reactive oxygen species, wherein the phenolic compound and the reactive oxygen species react at a target area in the presence of an oxidoreductase enzyme. | 2012-12-27 |
20120328711 | Antimicrobial system for selective, site-activated binding at target sites - The teachings provided herein generally relate to site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites. More particularly, the systems taught here include a phenolic compound bound to a reactive oxygen species, wherein the phenolic compound and the reactive oxygen species react at a target area in the presence of an oxidoreductase enzyme. | 2012-12-27 |
20120328712 | CARBON MONOXIDE RELEASING RHENIUM COMPOUNDS FOR MEDICAL USE - The present invention relates to new rhenium compounds of formula (I) | 2012-12-27 |
20120328713 | Articles of Manufacture with Improved Anti-microbial Properties - The invention pertains to methods and compositions for preventing or reducing microbial contamination using a silver (III) periodate as antimicrobial active hi a preferred embodiment the silver (III) periodate is used in a coating upon a medical device or implant to confer coating uniformity and antimicrobial efficacy. Also provided is a method of synthetising a silver (III) periodate in high yield by heating a source of single valency silver ions in water and subsequently combining it with a heated solution comprising persulfate, a by droxide, and a periodate. | 2012-12-27 |
20120328714 | EARLY DETECTION AND TREATMENT OF LUNG CANCER - This document provides methods and materials involved in the early detection of lung cancer (e.g., small cell lung cancer). For example, this document provides methods and materials for assessing nucleic acid obtained from a blood sample of a human for a CpG methylation site profile that, at least in part, indicates that the human has lung cancer (e.g., small cell lung cancer). | 2012-12-27 |
20120328715 | PREVENTION AND TREATMENT OF OSTEOCHONDROSIS IN ANIMALS AND HUMANS - A method of preventing or treating osteochondrosis comprising administering a therapeutically effective amount of a boron containing compound to a mammal in need of such treatment. | 2012-12-27 |
20120328716 | Composition to Preserve Insulations and Sealants and Method - The present invention is generally directed toward the preservation of insulations and sealants and more particularly to the protection of insulation and sealant products against insect attack through the use of inorganic borates. The present invention includes a polymer-based formulation derived from the reaction of an isocyanate component and a resin component. The resin component includes an inorganic borate incorporated therein. The incorporation of the inorganic borate can occur either at the time of the creation of the resin component or at a time after such creation. | 2012-12-27 |